Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Conn Med ; 65(10): 597-604, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11702518

ABSTRACT

The establishment of "best clinical practices" founded upon evidence-based medicine has become an increasingly important priority. Frequently, management guidelines are derived from published research data and disseminated among practitioners to help optimize patient care. The ultimate clinical impact of these guidelines in the "real world," however, is often clouded by an incomplete assessment of patient outcomes throughout the continuum of health-care delivery models. In order to address this gap in clinical outcome assessment, we propose to establish the Connecticut Cardiovascular Consortium. The Consortium will consist of a collaborative partnership among all 31 Connecticut hospitals working in concert with Connecticut Office of Health Care Access (OHCA). The primary objective of the Consortium will be to assess, compare, and optimize clinical outcomes among Connecticut residents with cardiovascular disease. As an initial goal for the Consortium, we further propose to undertake a prospective, observational study of Connecticut residents who present with ST Segment Elevation Acute Myocardial Infarction (STEMI). Recent advances in pharmacologic and mechanical reperfusion for STEMI have resulted in a need to define the optimal use of these therapies in the community at large. The primary purpose of this study will be to determine the relative merits of different treatment patterns for STEMI with regard to the use of fibrinolytic therapy and percutaneous coronary intervention (PCI). Particular emphasis will be placed on assessing the relative benefits of urgent mechanical revascularization performed at the state's seven tertiary facilities with PCI capability compared to all other treatment modalities. Successful completion of this unique collaborative endeavor is expected to have significant impact on improved patient care and on current health-care policy for medical resource allocation. Moreover, continued collaboration of health-care providers within the Connecticut Cardiovascular Consortium infrastructure should serve as a useful mechanism for ongoing improvements in evidence-based cardiovascular medicine and clinical research in the state of Connecticut.


Subject(s)
Heart Diseases/therapy , Outcome Assessment, Health Care , Connecticut , Evidence-Based Medicine , Humans , Myocardial Infarction/therapy , Research
2.
J Am Diet Assoc ; 95(4): 442-6, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7699186

ABSTRACT

OBJECTIVE: Despite the importance of dietary factors in treating and preventing heart disease, relatively little work has explored how well cardiac patients understand the nutrition information they are given. This study was designed to assess the nutrition knowledge and attitudes of cardiac patients. DESIGN: An onsite survey was administered to patients who were waiting to see their cardiologists. The survey focused on patients' medical history, attitudes toward nutrition, and knowledge of "heart-healthy" dietary information. SETTING: Cardiology practices in New England, Southern California, and the Midwest. SUBJECTS: A total of 606 patients completed the survey (roughly 74% of those approached). RESULTS: Most patients rated dietary factors as extremely important in treating and preventing heart disease, and 67.0% of those who had experienced a heart attack reported believing that diet had played a contributing role. Nonetheless, nutrition knowledge was marginal. Despite the fact that 92.4% of patients reported receiving dietary literature, overall accuracy rates on responses to nutrition questions did not exceed chance levels. Only 30.5% of the patients who were given dietary literature reported understanding it completely. CONCLUSIONS: Nutrition counseling should receive higher priority, both in medical training and in patient care, and cardiac patients should be referred to dietitians on a more routine basis. Physicians should not assume that patients who are given dietary information understand the materials they receive.


Subject(s)
Health Knowledge, Attitudes, Practice , Heart Diseases/psychology , Nutritional Physiological Phenomena , California , Chi-Square Distribution , Female , Humans , Male , Middle Aged , Midwestern United States , New England , Patient Education as Topic/standards , Surveys and Questionnaires
3.
N Engl J Med ; 309(13): 748-56, 1983 Sep 29.
Article in English | MEDLINE | ID: mdl-6888453

ABSTRACT

Milrinone, a derivative of amrinone, has nearly 20 times the inotropic potency of the parent compound and does not cause fever or thrombocytopenia in normal volunteers or in animals sensitive to amrinone. In 20 patients with severe congestive heart failure, intravenous milrinone resulted in significant decreases in left ventricular end-diastolic pressure (from 27 +/- 2 to 18 +/- 2 mm Hg), pulmonary wedge pressure, right atrial pressure, and systemic vascular resistance, as well as a slight reduction in mean arterial pressure. Significant increases occurred in cardiac index (from 1.9 +/- 0.1 to 2.9 +/- 0.2 liters per minute per square meter) and the peak positive first derivative of left ventricular pressure, with a slight increase in heart rate. Hemodynamic improvement was sustained during a 24-hour continuous infusion. Nineteen of the 20 patients subsequently received oral milrinone (29 +/- 2 mg per day) for up to 11 months (mean, 6.0 +/- 0.8), with sustained improvement in symptoms of heart failure. In 10 patients receiving long-term oral milrinone (greater than or equal to 6 months) radionuclide ventriculography showed continued responsiveness, with a 27 per cent increase in left ventricular ejection fraction after 7.5 mg of the drug. Four patients died after a mean of 4.8 months of therapy, and three patients with severe underlying coronary-artery disease and angina pectoris required additional antianginal therapy. No patient had fever, thrombocytopenia, gastrointestinal intolerance, or aggravation of ventricular ectopy. We conclude that milrinone shows promise for the longterm treatment of congestive heart failure.


Subject(s)
Cardiotonic Agents/therapeutic use , Heart Failure/drug therapy , Pyridones/therapeutic use , Administration, Oral , Adult , Aged , Cardiotonic Agents/administration & dosage , Cardiotonic Agents/pharmacology , Drug Evaluation , Female , Follow-Up Studies , Heart Failure/diagnostic imaging , Heart Ventricles/diagnostic imaging , Hemodynamics/drug effects , Humans , Injections, Intravenous , Male , Middle Aged , Milrinone , Pyridones/administration & dosage , Pyridones/pharmacology , Radionuclide Imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...